Motley Fool Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.47M	Sell	10,492 -2,034	-16%	-$692K	0.15%	115
2025 Q4	$4.98M	Buy	12,526 +3,480	+38%	+$1.54M	0.19%	113
2025 Q3	$4.12M	Buy	9,046 +2,394	+36%	+$975K	0.17%	112
2025 Q2	$2.17M	Buy	6,652 +623	+10%	+$172K	0.1%	148
2025 Q1	$1.63M	Buy	6,029 +4,130	+217%	+$1.06M	0.09%	151
2024 Q4	$447K	Buy	1,899 +139	+8%	+$36.6K	0.02%	178
2024 Q3	$486K	Sell	1,760 -130	-7%	-$33.8K	0.03%	165
2024 Q2	$460K	Sell	1,890 -70	-4%	-$11.1K	0.03%	167
2024 Q1	$293K	Sell	1,960 -75	-4%	-$12.5K	0.02%	199
2023 Q4	$390K	Sell	2,035 -196	-9%	-$33.4K	0.03%	181
2023 Q3	$395K	Sell	2,231 -48	-2%	-$9.16K	0.03%	181
2023 Q2	$433K	Buy	+2,279	New	+$452K	0.04%	172
2023 Q1	–	Sell	-2,181	Closed	-$518K	–	115
2022 Q4	$518K	Sell	2,181 -198	-8%	-$42.2K	0.06%	162
2022 Q3	$476K	Sell	2,379 -54	-2%	-$10.3K	0.05%	170
2022 Q2	$367K	Buy	2,433 +9	+0.4%	+$1.28K	0.03%	181
2022 Q1	$396K	Buy	2,424 +2,368	+4,229%	+$361K	0.03%	175
2021 Q4	$9K	Buy	+56	New	+$10.4K	﹤0.01%	188